SCHEMBL1745635

SCHEMBL1745635

CCC(C)(C)C(O)=S.CCCC(O)=S

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447082 0.84
SCHEMBL37528 0.79
SCHEMBL25238705 0.79 HDAC3 (0.44) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL11506222 0.79 HDAC3 (0.44) FFAR3HDAC3HDAC1HDAC2HDAC8
Hydrochloric Acid SCHEMBL9687182 0.76
SCHEMBL21462107 0.76
Hydrochloric Acid SCHEMBL3244716 0.76
SCHEMBL4293235 0.76
SCHEMBL307239 0.73 FFAR3 (0.40) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL29071751 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985424-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC. (US) 2011-07-26 US claimed
US-7981444-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2011-07-19 US claimed
EP-2325236-A1 Dendritic polymers with enhanced amplification and interior functionality Dendritic Nanotechnologies Inc. (US) 2011-05-25 EP claimed
JP-2008545621-A 2008-12-18 JP claimed
EP-1877103-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2008-01-16 EP claimed
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-12-27 US claimed
WO-2006115547-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-11-02 WO claimed
US-10968176-B2 Pyrrolidone derivatives, oligomers and polymers NANOSYNTHONS LLC (US) 2021-04-06 US disclosed
US-20190352258-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS NANOSYNTHONS LLC (US) 2019-11-21 US disclosed
US-10420849-B2 Pyrrolidone derivatives, oligomers and polymers NANOSYNTHONS LLC (US) 2019-09-24 US disclosed
US-20170246323-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS NANOSYNTHONS LLC (US) 2017-08-31 US disclosed
EP-3194365-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS Nanosynthons LLC (US) 2017-07-26 EP disclosed
WO-2016040962-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS NANOSYNTHONS LLC (US) 2016-03-17 WO disclosed
EP-1877103-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2008-01-16 EP disclosed
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-12-27 US disclosed
US-20070244296-A1 Dendritic Polymers with Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-10-18 US disclosed
EP-1737899-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2007-01-03 EP disclosed
WO-2006065266-A9 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2006-12-21 WO disclosed
WO-2006115547-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-11-02 WO disclosed
WO-2006065266-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality MYD88, TLR3, TMEM97 FFAR3 1358/4885HDAC3 3528/4885HDAC1 4450/4885
US-10968176-B2 Pyrrolidone derivatives, oligomers and polymers POF1B, VGF, RAB5IF FFAR3 977/4885HDAC3 3569/4885HDAC1 4294/4885
US-20190352258-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS POF1B, VGF, RAB5IF FFAR3 977/4885HDAC3 3569/4885HDAC1 4294/4885
US-20170246323-A1 PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS POF1B, VGF, RAB5IF FFAR3 827/4885HDAC3 3455/4885HDAC1 4328/4885
US-10420849-B2 Pyrrolidone derivatives, oligomers and polymers POF1B, VGF, RAB5IF FFAR3 827/4885HDAC3 3455/4885HDAC1 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.